key: cord-0983040-xo2om0uj
authors: Haji Abdolvahab, Mohadeseh; Moradi-kalbolandi, Shima; Zarei, Mohammad; Bose, Deepanwita; Majidzadeh-A, Keivan; Farahmand, Leila
title: Potential role of interferons in treating COVID-19 patients
date: 2020-11-03
journal: Int Immunopharmacol
DOI: 10.1016/j.intimp.2020.107171
sha: 0c047c480b6f715d37dd98f39b163af5ec518dc7
doc_id: 983040
cord_uid: xo2om0uj

The recently public health crises in the world is emerged by spreading the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) also named COVID-19. The virus is originated in bats and transported to humans via undefined intermediate animals. This virus can produce from weak to severe respiratory diseases including acute respiratory distress syndrome (ARDS), multiple organ dysfunction syndrome (MODS), pneumonia and even death in patients. The COVID-19 disease is distributed by inhalation via contaminated droplets or contact with infected environment. The incubation time is from 2 to 14 day and the symptoms are typically fever, sore throat, cough, malaise, fatigue, breathlessness among others. It needs to be considered that many infected people are asymptomatic. Developing various immunological and virological methods to diagnose this disease is supported by several laboratories. Treatment is principally supportive; however, there are several agents that are using in treating of COVID-19 patients. Interferons (IFNs) have shown to be crucial in fighting with COVID-19 disease and can be a suitable candidate in treatment of these patients. Combination therapy can be more effective than monotherapy to cure this disease. Prevention necessitates to be performed by isolation of suspected people and home quarantine as well as taking care to infected people with mild or strict disease at hospitals. As the outbreak of SARS-CoV-2 has accelerated, developing effective therapy is an urgent requirement to battle the virus and prevent further pandemic. In this manuscript we reviewed available information about SARS-CoV-2 and probable therapies for COVID-19 patients.

Coronaviruses exist in the subfamily of Orthocoronavirinae, in the family of Coronaviridae, the order Nidovirales, and realm Riboviria [1] . They are positive-sense single-stranded RNA (+ssRNA) viruses enclosed in an pleomorphic capsid with a helical symmetry [2] .

Coronaviruses are one of the largest RNA viruses with the genome consisting of about 26 to 32 kilobases [3] . These viruses called "Corona" means "crown" in Latin, because there are characteristic crown-like spikes on their surfaces [4] .

Coronaviruses are shared among birds and mammals, and trigger respiratory as well as intestinal infections in these creatures [5, 6] . They were considered to cause mild infections in humans until the epidemic of severe acute respiratory syndrome (SARS) in 2002 in China were appeared [4, [7] [8] [9] . Coronavirus 2019 (COVID- 19) or severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is quickly distributed in December 2019 from its origin in Wuhan City of China throughout the world and created a pandemic [5, 10] . Till August 4th 2020 around 18 million cases of coronavirus disease and 0.7 million deaths have been reported [11] . COVID-19 have transmitted to human from bats through unidentified animals [12] . Seven coronaviruses are photogenic in human but generally people get infected with four of them i.e. 229E, OC43, NL63, and HKU1. They commonly produce a respiratory infection vary from the normal common cold to severe diseases like Middle East Respiratory Syndrome (MERS), SARS and the recently revealed COVID-19 [1] . Since knowledge about this virus is promptly growing, readers are advised to be updated frequently [12] .

We here review the current data about epidemiology and pathology of this virus till diagnosis and potential treatment options. It is necessary to caution readers that every hour new information about diagnose, clinical trials, and treatment strategies for COVID-19 is updating.

On 31st December 2019, China announced the epidemic to the World Health Organization (WHO) and the Huanan sea food market was sealed. On January 7th, the virus was recognized as a coronavirus with more than 95% similarity to the bat coronavirus and more than 70% homology with the SARS-CoV [12] . It is identified that SARS-CoV-2 originated from bats and transmitted to human by an uncertain intermediate animal. This intermediate animal is suspected to be Pangolins, palm civet or snakes [10, 12] . When the virus infected intermediate mammals, it was transferred to the food market and spread there while obtaining further mutations before reached humans [12] .

The coronavirus disease increased rapidly and some cases did not in contact with live animal market, indicating sustained human-to-human transmission of coronaviruses [13] . The first death was announced on 11th January 2020. The number of COVID-19 positive people continued to growth rapidly in China and amplified quickly in other countries [14] [15] [16] . To date, COVID-19 is spread worldwide and more than 214 countries and territories around the world and 2 international conveyance are infected. By 11 th October 2020, 37508141 cases had been reported with 1078009 deaths and 28148081 recovered patients [15] .

SARS-CoV-2 evades human respiratory system and enter to the lung mucosa. Then, it distributes among people via inhalation of aerosol particles and droplets formed through talking, sneezing or coughing [10, 17] . In addition, people can be infected by contacting with contaminant surfaces and then rubbing the eyes, mouth and nose [12, 16] .

The SARS-CoV-2 is about 100 to 160 nm with the genome of 30000 nucleotides responsible to encode membrane, nucleocapsid, spike, and envelop proteins as well as several nonstructural proteins (nsp) (Fig. 1) . The lipid envelop encapsulates the nucleocapsid including nucleoprotein (N) and positive-sense single-strand RNA ((+) SSRNA) which let the virus to force human cells to produce virus particles. The N-protein binds to (+) SSRNA from its Nterminus and triggers viral transcription and replication. Membrane (M) protein, which is frequent on the surface of virus, has a pivotal role in assembly of SARS-CoV-2. The spike (S) glycoprotein is a transmembrane protein which comes outside the surface and regulate its attachment to the host cell receptors leads to entry of virus into the host cell [18] . The envelope (E) small protein composes the slight part of the virus and plays a crucial role in gathering of virus particles, interaction between virus and host cell, and penetrability of the host membrane [19] . Hemagglutinin-esterase (HE) is a dimer transmembrane glycoprotein that may have a role in virus entry. HE seems to be necessary for infection without having any role in viral replication [20] . Recent studies have been demonstrated that SARS-CoV-2 uses its spikes to attack the pulmonary tract's cells. These viruses attach to their target cells by angiotensinconverting enzyme 2 (ACE2) and entry into the cells [21] . The mechanism of entry and production of SARS-CoV-2 in the host cell is depicted in Fig. 2 .

The virus binds to ACE2 receptors on the surface of human cell with its S-protein. The Sprotein is cleaved by trypsin or furin proteases of the host cell and the mechanism of viral membrane fusion will be stimulated. Naturally, the virus enters into the cytoplasm of human cell by endocytosis and the mechanism of membrane fusion will be activated within endosomes [22] . Once, the virus releases from endosome to the cytoplasm, N-protein is started to degrade by proteasomes [23] , and the (+) SSRNA is completely unconfined into the cytoplasm.

Translation and replication of (+) SSRNA are arbitrated by the replication-transcription complex (RTC). The RTC encoded in viral (+) SSRNA and composed from nsp is supposed to provoke double membranes throughout the cytoplasm of the infected cell [24] . Following (+) SSRNA is translated to replicase proteins and these replicases apply the (+) SSRNA as a template to produce full-length negative-sense RNAs, which consequently use as templates in creating more genomes. SARS-CoV-2 structural proteins (i.e. S, E, and M) are manufactured in the cytoplasm following by translocation into the endoplasmic reticulum (ER), and then moving to ER-Golgi intermediate compartment (ERGIC) (Fig. 2 ) [25] . Furthermore, nucleocapsid is shaped in the cytoplasm by sheltering of (+) SSRNA with N-protein.

Afterward, they combine inside the ERGIC membrane leads to self-assembly of novel virions.

Lastly, these virions are distributed from contaminated cells to other cells by exocytosis.

Meanwhile, the infected cell is dead due to the pressure of viral replication on ER. Taking into account that the exact mechanism of action for SARS-CoV-2 is quiet unidentified [20] . 

Generally, patients with COVID-19 disease experience similar symptoms of common cold and flu, whereas some of them never show any symptoms. Symptoms are varied from fever, sneezing, cough, and shortness of breath to throat pain, pneumonia, and acute respiratory distress syndrome (ARDS) [26] . In a group of patients, after a week the disease can lead to pneumonia, ARDS and death; because of the tremendous increase of inflammatory cytokines such as IL2, IL7, IL10, IP10, GCSF, TNFα, MCP1 and MIP1A [27] . Overall, around 80% of COVID-19 patients represent mild symptoms, around 15% of cases are infected severely, and 5% of them are censoriously ill and may leads to Pneumonia [10, 12] . Symptoms could develop in 2 to 14 days after exposure to coronavirus. However, on average, the incubation time is around 5 days [28, 29] .

Side effects and mortality are generally observed in old patients or patients with comorbid illnesses. Fatality rate in these patients is 50-75%; while this rate in adult patients is 4 to 11%.

Overall, the fatality rate in COVID-19 patients is between 2 and 3% [12, 15] . Severity of disease in infants, children and young people has also been stated to be considerably slighter than the adult patients. Rarely, multiorgan dysfunction and pneumonia in children as well as mild infection in the neonatal have been reported [30, 31] .

The standard method to diagnose COVID-19 is reverse transcription polymerase chain reaction (RT-PCR) from a nasopharyngeal or throat swab. Furthermore, chest computed tomography (CT) scan for pneumonia and identification of several symptoms can be applied for diagnosis [32] .

Once the virus enters the host cell, the immune system of the host distinguishes the virus, inducing the innate and adaptive immune responses. Immune cells, particularly Toll-like receptors (TLR) 3, 7, and 8, recognize the virus using pathogen recognition receptors (PRRs) followed by improved interferon (IFN) production. During SARS-CoV and MERS-CoV infection, the activity of host innate immune cells is reduced by their non-structural proteins, leads to change in cytokine production [33] [34] [35] . Humoral immune response to SARS-CoV-2 is similar to other coronaviruses, including the IgM and IgG production. B cells prompt immune response against the N-protein at the beginning of COVID-19 infection, where as antibodies against S-protein can be identified after 4 to 8 days from the preliminary symptoms [36, 37] . N-protein is smaller and more immunogenic than S-protein, and as it is unglycosylated N-specific neutralizing antibodis are produced at an early phase of acute disease [38] . SARS-CoV-specific antibodies including IgM, IgA, and IgG were identified in patients after the appearance of symptoms at several time points. IgM and IgA were produced after 5 days, and IgG after 14 days of initial symptoms [39] . In addition, IgG was preserved for a longer period than IgM which was started to reduce after 3 months [40, 41] . In a study on 16 [43] .

Not only neutralizing antibodies are useful in defense against viruses, but also non-neutralizing antibodies can help APCs and other immune cells. Formerly remaining SARS-CoV antibodies may support the viral contagion in Fc receptor (FcR)-expressing cells [44] . The entry of virus through ACE2-independent pathway does not lead to viral replication; somewhat, viral flaking by macrophages augments tissue damage by myeloid cell stimulation. This viral entry via nonneutralizing antibody followed by abnormal stimulation of immune cells is entitled antibodydependent enhancement (ADE) [44, 45] . ADE has been detected in numerous viral infections, such as MERS and SARS. In the case of MERS, a neutralizing antibody directing RBD to enter into the host cell through dipeptidyl peptidase 4 (DPP4) pathway. While SARS viruses can enter into the FcR-expressing cell via ADE using anti-S antibodies were observed to be involved in ADE to gain entry into FcR-expressing cells [46] , while in MERS, a neutralizing monoclonal antibody targeting RBD helped this virus to entry through the DPP4 pathway [47] .

Overall, the immunopathology of COVID-19 is almost similar in MERS and SARS infections.

Current studies have shown that elevated cytokine levels (e.g. TNFα, IL-6, and IL-10) and

lymphopenia related to the severity of COVID-19 infection [13] . Moreover, along with the diminished number of T cells, the remaining T cells exhibits dysfunction [48] . In severe COVID-19 cases, this dysfunctional immunity can prime a cytokine storm, leading to enhanced respiratory pathology and pulmonary pain as well as a elevated risk of poor clinical results and death. Thus, using antiviral drugs alone might not be enough to inhibit the distressing cytokine storm and respiratory devastation in COVID-19 patients.

Further investigation is required to understand the exact mechanism underlying the viral attack to the host cells and dysregulation of the immune system in COVID-19 patients to be able to develop efficient vaccines and and treatment strategies [49] .

In a study performed on cytokine profile of severe COVID-19 patients, meaningful promotion of cytokines such as IFN-γ, IL-1β, IL-1ra, MCP-1, MCP-3, and IP-10 were detected in sever COVID-19 infections. Furthermore, IFN-γ, TNF-α, IL-2, and IL-1β from T helper-1 cells as well as IL-4, IL-10 produced by T helper-2 cells were observed concurrently [13] . The number of CD4 and CD8 molecules and lymphocytes were negatively associated with cytokine secretion, representing a potential correlation between adaptive immunity and cytokine storm.

In mild COVID-19 cases, the number of lymphocytes regularly diminished to its normal level till be undetectable. In acute COVID-19 infections, lymphocytes boosting was not accompanied by cytokine storm [50] . This may be because of viral clearance by a cellular immunity at the early stages, and cytokine inhibition by innate immunity leads to disease improvement.

In a study on COVID-19 patients, the insistent production of GM-CSF and IL-6 has been identified represented the pathogenic effect of innate immunity [51] . In another study, the substantial increase was observed for IFN-α. Type I IFNs stimulating pathway and interferonstimulated gene (ISGs) were both induced; however, ISGs expression was not observed in PCMBs, signifying the pivotal role of pDCs in production of type I IFNs [52] . It has been demonstrated that type I IFNs positively associated with disease harshness, which was not observed in SARS infection, as defecated type I IFN-signalling was negatively related to fatal SARS. All together, these investigations showed that type I IFNs might organize an unbalanced immune reaction leading to COVID-19 worsening [51] .

Inflammation is a critical reaction of the immune system to eradicate infections in response to pathogens. The pathogens then regulate the employment of activated immune cells and finally refurbishment of homeostasis and tissue healing. However, SARS-CoV-2 stimulates extreme and sustained cytokine/chemokine responses in several patients called cytokine storm [53] .

In a study on acute COVID-19 patients, it has been shown that cytokine storm can consequently dysregulate inflammation leads to disease deterioration [27] . 

Immunological characteristics of MERS-CoV, SARS-CoV, and SARS-CoV-2 infections are different among patients. The IFN expression is various among MARS-CoV, SARS-CoV and SARS-CoV-2 infections. For instance, SARS-Cov-2 is less potent to induce type I IFNs in animal models and in vitro than SARS-CoV and other lung viruses, which may indicate the significant role of IFNs in COVID-19 [55] [56] [57] . In COVID-19 patients, despite limited number of immune cells like pDCs produced type I IFNs, it was sufficient to stimulate ISGs.

SARS-CoV-2 stimulated lower level of type I IFNs in comparison with SARS-CoV, although it replicated more effective in human respiratory tissues [58] [59] [60] [61] . A feeble type I IFN expression might be a sign of other coronavirus diseases such as MERS-CoV [62] , the mouse hepatitis virus (MHV) or the porcine epidemic diarrhea virus (PEDV) [63, 64] . Certainly, coronaviruses have several strategies to produce type I IFNs and hide or escape from immune system of the host [55] .

In MERS-CoV lower IFN active antagonism was observed rather than IFN aggression in SARS-CoV, which may lead to elevated sensitivity to anti-viral effect of IFNs [65] . MERS-CoV similar to SARS-CoV could down-regulate ISG responses [66, 67] . Furthermore, delayed and reduced expression of type I IFNs were detected in both infections [68] . However, contrary to MERS infection‫ﻭ‬ in SARS atypical IFN effect was observed and the lack of type I IFNs enhanced clinical outcome instead of inducing pulmonary immunopathology [39] . Early injection of type I IFNs in infected mice could rescue them from death despite the downregulation of cytokine-associated genes. IFN signaling not only modulate anti-inflammatory response during the acute stage of infection, but also regulate adaptive immune activity in severe MERS infection [69] .

As COVID-19 pandemic is escalating every day, finding an effective therapy is urgent. Every day, a new strategy for COVID-19 treatment is introduced. There is no assured treatment for COVID-19 yet. However, treatment emphases on supportive care, symptomatic therapy, oxygen therapy and respiratory support, fluids, antiviral drugs, and boost the immune system of patients. Most of these drugs have represented some benefits in COVID-19 therapies; however, it is not unexpected to observe failure in future (11).

All positive patients for COVID-19 require resting and supportive treatment, confirming sufficient water intake and calorie to diminish the possibility of dehydration. Water, electrolyte and osmotic balance need to sustain in company with the of monitoring oxygen saturation, blood count, urine test, C-reactive protein, myocardial enzyme range, kidney and liver function, and all health warning signs. Chest imaging and arterial blood gas need to be incessantly tested when required [10] .

Sever cases with high fever need to be controlled continuously. Warm bath and antipyretic medications should be used to decrease the high fever in patients with the temperature more than 38.5 °C. Common antipyretic drugs include ibuprofen and paracetamol (acetaminophen) are administrated orally, 5-10 mg/kg and 10-15 mg/kg every time, respectively. Sedatives may also be administed in case of a seizure in children [10, 70] .

Inhaling of oxygen is applied in more severe cases. Hypoxia can occur when the virus invading the lungs. Oxygen therapy using oxygen mask and nasal catheter should be rapidly supplied to these patients. In emergency medical conditions, invasive or non-invasive mechanical ventilation (NIV) need to be provided for the patients [71] .

Children who cannot endure NIV or can tolerate NIV for around 2 hours with no progress, require invasive ventilation (IV) immediately. The IV should acquire low tidal volume ventilation (LTVV) to protect lung and diminish ventilator-associated lung injury (VALI). In addition, lung recruitment, prone-position ventilation, or extracorporeal membrane oxygenation (ECMO) may be required.

In accordance with fluid replacement, monitor hemodynamics, refine microcirculation, and employ vasoactive agents if necessary [70] .

Several therapeutics are applied in COVID-19 patients, despite the safety and efficacy of some of them are questionable [72] . The function, positive and negative effects of antiviral agents including Arbidol, Foscarnet, Remdesivir, Ribavirin, Favipiravir, Galidesivir, Camostat, Umifenovir, Darunavir, Lopinavir/ Ritonavir, and Oseltamivir, antibody and stem cell therapies as well as other medicines are depicted in Table 1 . 

IFNs are natural broad-spectrum antiviral and anti-inflammatory proteins which bind to their receptors on the surface of different cells and induce JAK-STAT signaling pathway, followed by transcription of IFN-stimulated genes (ISGs) including the antiviral enzyme RNAse L, and the proinflammatory chemokine CXCL10 [60, 129] .

Type 1 IFNs are a group of cytokines including α, β, ω, ε and κ subtypes [130] . In contrast, type III IFNs act milder, because they typically decline viral replication in infected cells. Another special characteristic of type III IFNs is that they can support epithelial barrier constancy. [132] .

A study on SARS-CoV showed a successful type I IFN therapy [133] , where as another research on larger group hardly revealed any positive effect [134] . Early implementation of IFNs has special benefits in lessening virus counts and clinical symptoms of COVID-19. However, it rarely reduces fatality rates [136, 137] . It has also been proposed that IFNs were effective in some patients [138, 139] . Subtype variety could be one of the reason of contradictions among studies. Further details about each type of IFNs are described is separate sections below. Table 2 depicted some principal information about IFNs. [132, 135] proinflammatory response/ kill infected cells/ neutralize the virus/ immune regulator/ induces regulatory T cells and antigenspecific regulatory B cells [142, 144] few side effects including flu-like syndrome/ headache/ fever/ abdominal pain [144] a bone disorder/ an immune deficiency syndrome/ allergic diseases/ cancers/ infections/ chronic granulomatous disease/ osteoporosis/tuberc ulosis/hepatitis/ scleroderma [144] stimulates cytokine expression/ improves immune response/ expands destruction of CTL/ restricting virus replication and distribution [145] III IFN-λ epithelial cells/ limited subset of immune cells like plasmacytoid dendritic cells [140, 144] less inflammatory response/ reduce viral replication and diffusion/ stimulate epithelial barrier stability/ inhibit the recruitment of neutrophils [135] few side effects [140] Infections/ autoimmune diseases/ hepatitis [140] modulating immunity/ antiviral immunity in the respiratory tract/ induces several antiviral genes in epithelial cells/ control of viral infections in epithelial cells of both respiratory and gastrointestinal tracts/ proinflammatory activity in the lungs [146, 147] This finding representing the probability of IFN-α2b in treating COVID-19 disease [148] .

represented that early usage of IFN-α2b could diminish in-hospital death compare to patients who didn't received IFN-α2b. However, IFN-α2b administrated in late stage raised mortality.

Among survived patients, early administration of IFN-α2b could not improve CT scan or hospital release, while late IFN-α2b causes postponed recovery. Therefore, IFN-α2b administrated throughout the early phase of COVID-19 disease is associated with promising clinical outcomes [149] .

IFN--1a has been demonstrated to be beneficial in treating virus diseases such as hepatitis [150] and SARS-CoV [131, [151] [152] [153] . Because of the high similarity of SARS-CoV with SARS-CoV-2, IFN--1a was added to the antiviral drugs using in COVID-19 patients. SARS-CoV-2 enters the cell by binding to ACE2 receptor, and its expression is begun leads to induction of innate immune system [60, 131, 154] . Generally, IFNs are produced after viral infection to hinder the infection. However, several studies have shown that despite its effectiveness in restraining the SARS-CoV replication, IFNs expression was reduced during infection with SARS-CoV [60] . Recent studies represented that IFN--1a enhanced ARDS difficulties [15] . Using IFN--1a significantly augmented the rate of discharge on day 14 and declined 28-day death. There is no published data regarding to the administration of IFN--1a

in patients with acute COVID-19. However, early use of IFN--1a, in severely ill instinctively ventilated patients elevated survival rate. Late administration hardly exhibited any benefits. In this randomized clinical trial efficacy and safety of IFN--1a has been evaluated in patients with severe COVID-19 [155] .

Notably, IFN-β-1a displayed potent antiviral function at dosages that have been accepted in animals due to its safety profiles [143] . The administration route is another critical aspect in treatment of COVID-19 patients with IFN-β-1a. Both intravenous (i.v.) and subcutaneous (s.c.)

administration routes are considered to be suitable in therapy. However, because of various bioavailabilities of IFN-β-1a through i.v. and s.c. administrations this feature requires to be taken in to account more seriously, particularly in critically sick patients [156] .

Side effects of IFN--1a were hypersensitivity reaction, neuropsychiatric issues, and injectionrelated problems which all were endurable and recovered through the follow-up medical care [155, 157] .

On 20th July 2020, Synairgen PLC announced positive results of phase II trial on the novel formulation of IFN--1a, called SNG001, in hospitalized 220 COVID-19 patients. SNG001 is a spray to deliver IFN--1a to the lungs via nebulization to treat LRTI caused by SARS-CoV-2 viruses. The patients with chronic obstructive pulmonary disease (COPD) or asthma inhaled SNG001 tolerated the drug very well and exhibited improved lung function and recovery rate as well as reduced breathlessness and mortality rate [158] .

Recent study on IFN--1b depicted its potential in vitro to inhibit SARS-CoV and MERS-CoV.

In another study, it also hindered SARS-CoV-2 virus effectively. Therefore, some guidelines suggest the subcutaneous administration of IFN--1b accompanied by other antiviral drugs.

Recently, the efficacy of IFN--1b in COVID-19 patients with moderate to severe pneumonia who hospitalized between 23th February to 4th April, 2020 was explored. Patients received 3 to 5 dosages of IFN--1b subcutaneously and endpoint of the study was in-hospital fatality.

Patients who received IFN--1b were also receive lopinavir/ritonavir and hydroxychloroquine.

The total mortality rate was about 20% in patients who received IFN--1b compared to 27%

of counterparts who did not use this drug. IFN--1b administration time in viral disease has been displayed its significance in successful therapy in mouse models.

Although IFN--1b therapy reduced in-hospital mortality in patients because of the combination therapy in many patients, it is hard to assign effectiveness to any one drug [159] .

In a recent retrospective study on COVD-19 patients with mild or moderate disease treated with IFN--1b, despite small number of patients meaningful efficiency and no mortality were observed. Thus, this result confirms that IFN--1b is a potential therapeutic agents for SARS-CoV-2 [138] .

Early enrolment to organize doses of IFN--1b is crucial; however it might be unrealistic as patients hardly present in hospital sooner than 7 days, when disease features usually worsen [160] . It was regularly displayed that IFNβ is more effective than IFNα to hinder COVID-19 [161] . Among IFN-I subtypes, IFNβ-1a and -1b were the greatest effectiveness subtype in preventing COVID-19 patients [143] . This reality can be associated to the defensive function of IFNβ in the lung, preservation of endothelial barrier activity and increasing antiinflammatory adenosine [141] .

IFN- is an immunoregulatory protein with a broad-spectrum antiviral and antimicrobial functions which has influence on multiple cells and cellular activities [162, 163] . It has been demonstrated that IFN- initiates its antiviral activity using cellular function at multiple stages [145] . At the beginning, IFN- binds to its receptor and subsequently induces several genes resulted in declining virus replication [164] . Otherwise, IFN- stimulates cytokine expression by activation of monocytes, macrophages, and T cells. Furthermore, it expands destruction of cytotoxic T lymphocyte (CTL) by inducing major histocompatibility complex (MHC) class I, or granzyme B. In addition, it improves immune response by stimulation of MHC class II receptors [165] . Recent studies on treatment of coronavirus infection with IFN- represented its pivotal role in restricting virus replication and distribution inside the retina and protecting host cells throughout a retinal infection [145] .

Current experimental studies demonstrate that IFN- production by retinal cellular infiltration is a critical function of an immune response accountable for noncytolytic virus clearance from the retina [145] . There are some clinical protocols about dosage and treatment duration of IFNγ. Hopefully, few adverse effects are detected for this available and cheap therapeutic. The safety of IFN-γ has already been approved but its efficacy needs to be confirmed. IFN-γ is recently suggested to be used in virus pandemics, particularly for endangered patients when exact therapeutics are not obtainable [144] .

IFN-α and β [166] . Furthermore, IFN-λ prohibit the employment of neutrophils to the location of inflammation [167] . MERS-CoV and SARS-CoV principally invade to alveolar epithelial cells (AEC). As IFN-λ induces several antiviral genes in epithelial cells, leading to antiviral activities, it can be a proper candidate for an effective treatment.

To date, the only available therapeutic IFN-λ in the market is pegylated IFN-λ1 (peg-IFN-λ1).

In vitro, IFN-λ therapy represented efficacy against different viruses, including MERS-CoV and SARS-CoV-2 [140] . The key activity of IFN-λ is to hinder viral infection by inducing an antiviral response and, if infected, to reduce viral production and diffusion. In treatment of COVID-19, the lack of proinflammatory activity in the lungs is one of the significant benefits of IFN-λ compare to type I IFNs [140, 166] . However, it needs to be determined if immune system is reactive to IFN-λ in COVID-19, as the immune cells impair inflammation.

Additionally, it needs to be investigated that if antiproliferative effect of IFN-λ could hamper recovery procedures of epithelial cells and virus-induced apoptotic cell death [140] .

Indeed, IFN-λ can induce an antiviral effect in cells with IFN-λ receptor 1 (IFNLR1). For COVID-19, it is uncertain whether alveolar endothelial cells or macrophages are effectively infected and supported viruses to not be available to IFN-λ antiviral function for absence of IFNLR1. Although IFN-λ may be more suitable than type I IFNs in anti-COVID-19 therapy, more studies are required to analyze probable negative effects of IFN-λ.

Even though not yet administrated in active COVID-19 infection, no improved lung infections have appeared in 3,000 patients who were preserved for 48 weeks with peg-IFN-λ1. Probable side effects might also be diminished by shorter treatment period [140] .

There are many outstanding questions in relation to COVID-19 and IFN-λs, however it could be beneficial in this pandemic outbreak.

A combination of IFN-α-2a with ribavirin postponed mortality rate [136] and displayed efficient outcomes in the rhesus macaque, but was questionable in human [141] . In China, the administration of 5 million U of IFNα twice a day accompanied with ribavirin in COVID-19 patients is recommended [141] . Administration of IFNβ with lopinavir/ritonavir enhanced pulmonary function without declining virus production or lung injury in COVID-19 infection [168] . In general, the combination of type I IFN with remdesivir, ribavirin, or lopinavir/ritonavir could elevate its efficacy in COVID-19 [168] . It might also be applicable to treat COVID-19 patients with type III IFN due to its shielding property in the pulmonary tract [169] .

In clinical trials performed on 4th May 2020 on COVID-19 patients, treating with the combination of opinavir/ritonavir, chloroquine/hydroxychloroquine, and plasma therapy were further studies with more patients may be needed to approve these results.

In a randomised phase 2 clinical trial in COVID-19 patients, a triple combination of an injectable IFN--1b, with an oral nucleoside (ribavirin) and protease suppressor (lopinavirritonavir), administrated in 7 days of symptom beginning, was inhibited the flaking of SARS-CoV-2 [171] .

Overall SARS-CoV-2 is more delicate to type I IFNs than other therapeutics. The data of IFN therapy against COVID-19 executed in China will be published in a near future. This data should reveal more accurate information about this therapy [141] .

In conclusion, combination therapy with various drugs in different stages of this pandemic could be more efficient than monotherapy [172] . We hope the ongoing clinical trials scheduled to be finished in 2020, may assist us to find the most effective therapeutics to treat COVID-19

in this year.

To date, there is no particular medicine or vaccine to abort symptoms efficiently and treat patients. Therefore, prevention is the only way to protect yourself from this virus by staying at home, covering your mouth when coughing, washing your hands often, keeping a safe distance from others and self-isolating for 14 days when you suspect to be infected [17] .

Some virus characteristics make prevention problematic particularly, spreading from asymptomatic and even recovered people, various features of this disease, prolonged incubation time, the contamination even before initiation of symptoms, and extensive disease period. Not only infected cases, but also suspected people need to be quarantined at home.

Indoor ventilation with sunlight is recommended to destruct the viruses [12, 173] .

Having strong immune system is the most vital defense against different diseases. People with healthy body and immune system could better fight with disease. When the immune system is droning, people need to strengthen their body potency. People should focus on their health with daily sport activities and nutrients that support and improve the length of their life in health.

During COVID-19 pandemic, get sufficient sleep, sunlight and fresh air everyday [10] . In addition, people should escape from crowded and closed areas, postpone their trip to other places, wear a mask, and follow all hygiene rules. Especially older adults and people with any comorbidities should be more careful about these guidelines. There is a high risk of transmission of SARS-CoV-2 to healthcare workers which was happened in 21% of healthcare workers in 2002 [174] . Therefore, all interactions particularly healthcare workers need to be checked for progress of any COVID-19 symptoms. COVID-19 patients have to wear surgical masks and should be isolated and maintained in separate rooms. In hospital sometimes negative pressure rooms are used. Patients can leave the solation room when they have no fever for more than 3 days and have no positive molecular test from 1 sample in two repeated measurements [12, 175] . In China, new regulations about trading of animals are introduced to inhibit viral transmission form animal to human or vice versa [32] .

Furthermore, travel restrictions are extended from China to all over the world to test and isolate suspected passengers for COVID-19. Whether these regulations could slow down the viral distribution is not known [176] .

COVID-19 outbreak has challenged the public health, medical and economic infrastructure of the world. This viral infection can reveal by fever or pneumonia. In passing time, we will know how this virus will influence our lives. The current mortality rate of COVID-19 infection based on the approved cases and fatalities is about 2%. There are several pulmonary supportive therapies besides antiviral drugs, these are mainly used in sever COVID-19 cases. However, the pathogenesis of the virus as well as immune deficiency of the host in acute patients need to be considered to balance the advantage and risk ratio before beginning therapy. The higher fatality rates in elder could be described by the developed IFN activities threshold. 

All authors contributed to the writing of this manuscript; the funding agencies did not have any role. The authors read and approved the final article.

None to declare.

The authors declare no conflict of interest.

Origin and evolution of pathogenic coronaviruses

Feigin and Cherry's Textbook of Pediatric Infectious Diseases

Coronavirus genomics and bioinformatics analysis

Aetiology: Koch's postulates fulfilled for SARS virus

Virus Taxonomy-Ninth Report of the International Committee on Taxonomy of Viruses

Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome

A Review of COVID-19 (Coronavirus Disease-2019) Diagnosis, Treatments and Prevention

A Review of Coronavirus Disease-2019 (COVID-19)

Clinical features of patients infected with 2019 novel coronavirus in

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

World Health Organization, Coronavirus Disease (COVID-19) Situation Reports

Pre-fusion structure of a human coronavirus spike protein

In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel

Novel 2019 coronavirus structure , mechanism of action , antiviral drug promises and rule out against its treatment

The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

Interactions of SARS Coronavirus Nucleocapsid Protein with the host cell proteasome subunit p42

Replication/Transcription Complexes Are Membrane-Protected and Need a Host Factor for Activity In Vitro

The molecular biology of coronaviruses

COVID-19 and Multiorgan Response

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

The COVID-19 epidemic

Dynamics of peripheral immune cells and their HLA-G and receptor expressions in a patient suffering from critical COVID-19 pneumonia to convalescence

Antioxidants, cytokines, and influenza infection in aged mice and elderly humans

Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome

IL-17 boosts proinflammatory outcome of antiviral response in human cells

Critical role of IL-17RA in immunopathology of influenza infection

Cell Host Response to Infection with Novel Human Coronavirus EMC Predicts Potential Antivirals and Important Differences with SARS Coronavirus

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice

SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon

CXCL10-CXCR3 enhances the development of neutrophil-mediated fulminant lung injury of viral and nonviral origin

SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism

Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome

Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome

Antibody Responses Against SARS Coronavirus Are Correlated With Disease Outcome of Infected Individuals

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease

COVID-19 | Predicted Immune responses | InvivoGen

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

The Comparative Immunological Characteristics of SARS-CoV , Coronavirus Infections

Viral Invasion and Type I Interferon Response Characterize the Immunophenotypes during Covid-19 Infection

The pathogenesis and treatment of the 'Cytokine Storm'' in COVID-19

Aveolar Macrophage Activation and Cytokine Storm in the Pathogenesis of Severe COVID-19 CURRENT STATUS : UNDER REVIEW

Interplay between SARS-CoV-2 and the type I

Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Inhibition of Beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3

Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis

Severe acute respiratory syndrome coronavirus fails to activate cytokine-mediated innate immune responses in cultured human monocyte-derived dendritic cells

Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures

Suppression of type I interferon production by porcine epidemic diarrhea virus and degradation of CREB-binding protein by nsp1

Inhibition of the alpha/beta interferon response by mouse hepatitis virus at multiple levels

Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus

Pathogenic Influenza Viruses and Coronaviruses Utilize Similar and Contrasting Approaches To Control Interferon-Stimulated Gene Responses

GMXPBSA 2.1: A GROMACS tool to perform MM/PBSA and computational alanine scanning

Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment

IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes

Diagnosis and treatment protocol for novel coronavirus pneumonia

What's New in the Guidelines

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Novel coronavirus: where we are and what we know

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19

Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Severe acute respiratory syndrome (SARS) and coronavirus testing--United States

Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from

Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein

Arbidol for preventing and treating influenza in adults and children

A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections

Gains and losses in translation of SDGs at sub-national levels

Ribavirin therapy for severe COVID-19: a retrospective cohort study

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

Favipiravir: a new medication for the Ebola virus disease pandemic

Use of Favipiravir to Treat Lassa Virus Infection in Macaques

Favipiravir: A new and emerging antiviral option in COVID-19

Molecular Mechanisms of Galidesivir as a Potential Antiviral Treatment for

A study to evaluate the safety, pharmacokinetics and antiviral Effects of Galidesivir in Yellow Fever or COVID-19

A phase 1 / 2 trial to evaluate the pharmacokinetics , safety , and efficacy of NI-03 in patients with chronic pancreatitis : study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis ( TACTIC )

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity

Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol

Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19

Lopinavir/Ritonavir and Other HIV Protease Inhibitors, n.d

Bioorganic Chemistry Is oseltamivir suitable for fighting against COVID-19 : In silico assessment , in vitro and retrospective study

An Update on Current Therapeutic Drugs Treating COVID-19

gov Identifier: NCT04327388, Sarilumab COVID-19, n.d

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response / intolerance to tumour necrosis factor inhibitors

Interleukin-6 Inhibitors. COVID-19 Treatment Guidelines

Tocilizumab in patients with severe COVID-19 : a retrospective cohort study

Tocilizumab among patients with COVID-19 in the intensive care unit : a multicentre observational study

Regeneron Antibody Therapy For Covid-19 Enters Late-Stage Trials

Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors

Mesenchymal stem cells : current clinical progress in ARDS and COVID-19

Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use

The immunomodulatory function of mesenchymal stem cells: mode of action and pathways

Targeting macrophage subsets for infarct repair

Roles of flavonoids against coronavirus infection

Potential of Flavonoid-Inspired Phytomedicines against COVID-19

Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro

The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review

COVID-19 : The In fl uence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients

Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB

COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers

SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?

Preventing a covid-19 pandemic

Sacubitril/valsartan in COVID-19 patients: the need for trials

Biomedicine & Pharmacotherapy The role of Interleukin 6 inhibitors in therapy of severe COVID-19

Rethinking interleukin-6 blockade for treatment of COVID-19

Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis

Interferon-stimulated genes: a complex web of host defenses

Antiviral Actions of Interferons

Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response

Unraveling the complexities of the interferon response during SARS-CoV infection

Interferon Alfacon-1 Plus Corticosteroids in Severe Acute Respiratory SyndromeA Preliminary Study

Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China

Interferon Responses Could Explain Susceptibility to Severe COVID-19. Impaired or delayed antiviral signaling could be a treatable cause of serious COVID-19

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study

Coronaviruses -drug discovery and therapeutic options

Interferon beta-1b for COVID-19

Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: An observational study

COVID-19 and emerging viral infections: The case for interferon lambda

Type 1 interferons as a potential treatment against COVID-19

Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV)

Interferon-β 1a and SARS Coronavirus Replication

IFN-γ as a Major Antiviral Therapeutic for Viral Epidemics , Including Severe Acute Respiratory Syndrome Coronavirus 2 ( SARS-CoV-2 ): A Clinically Forgotten but Potential Antiviral Cytokine and Non-Virus-Specific Antiviral as a

The critical role of IFN-γ in experimental coronavirus retinopathy

Lambda Interferon Renders Epithelial Cells of the Respiratory and Gastrointestinal Tracts Resistant to Viral Infections

COVID -19: lambda interferon against viral load and hyperinflammation

Interferon-α2b Treatment for COVID-19

Clinical and Translational Report Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients Clinical and Translational Report Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients

Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients

Characterization and antivirus activities of a novel bovine

Ribavirin and interferonbeta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines

Relationship to Duration of Infection

Efficacy and safety of interferon β-1a in treatment of severe COVID-19: A randomized clinical trial

Interferon beta-1a for COVID-19: critical importance of the administration route

A. the M. trial group, Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial

COVID-19 -SG016 Clinical Trial Data Readout

Study evaluates the effectiveness of interferon beta 1b in COVID -19 pneumonia

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

SARS: Systematic review of treatment effects

Direct Antiviral Mechanisms of Interferon-Gamma

Interferon-gamma: a historical perspective

The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion

Cytokine-mediated control of viral infections

IFN λ is a potent anti-influenza therapeutic without the inflammatory side effects of IFN α treatment

IFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β production

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV

COVID-19 : An Update About the Discovery Clinical Trial

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Clinical trials on drug repositioning for COVID-19 treatment

Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM), A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)

Correspondence workers from subclinical coronavirus infection

World Health Organization, Coronavirus disease [COVID-19] Technical Guidance: Infection Prevention and Control

Game consumption and the 2019 novel coronavirus

 COVID-19 disease, the recently public health crises in the world, is emerged by spreading the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).  This virus can produce from weak to severe respiratory diseases including acute respiratory distress syndrome (ARDS), multiple organ dysfunction syndrome (MODS), pneumonia and even death in patients. Developing effective therapy is an urgent requirement to battle the SARS-CoV-2 virus and prevent further pandemic.  Interferons (IFNs) have shown to be crucial in fighting with COVID-19 disease and can be a suitable candidate in treatment of these patients. Combination therapy can be more effective than monotherapy to cure this disease.